Last reviewed · How we verify
anti-lymphocyte globulin
Anti-lymphocyte globulin (ALG) is a polyclonal antibody preparation that depletes T lymphocytes by binding to lymphocyte surface antigens and promoting their destruction.
Anti-lymphocyte globulin (ALG) is a polyclonal antibody preparation that depletes T lymphocytes by binding to lymphocyte surface antigens and promoting their destruction. Used for Aplastic anemia, Acute graft-versus-host disease (GVHD) prophylaxis and treatment, Organ transplant rejection prevention.
At a glance
| Generic name | anti-lymphocyte globulin |
|---|---|
| Also known as | NST conditioning reginmen |
| Sponsor | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences |
| Drug class | Polyclonal antilymphocyte antibody |
| Target | T-lymphocyte surface antigens (pan-T-cell markers) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
ALG is derived from animal serum (typically rabbit or horse) immunized against human lymphocytes. It contains multiple antibodies that recognize and bind to T-cell surface markers, leading to complement-mediated lysis and antibody-dependent cellular cytotoxicity. This results in profound T-cell depletion, suppressing cell-mediated immunity and reducing rejection responses or pathogenic lymphocyte-driven inflammation.
Approved indications
- Aplastic anemia
- Acute graft-versus-host disease (GVHD) prophylaxis and treatment
- Organ transplant rejection prevention
Common side effects
- Fever and chills
- Thrombocytopenia
- Leukopenia
- Serum sickness
- Infection (due to immunosuppression)
- Rash
Key clinical trials
- Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (PHASE1, PHASE2)
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (PHASE2)
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (PHASE1, PHASE2)
- Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery (PHASE1, PHASE2)
- Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (PHASE1)
- Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (PHASE2)
- Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors (PHASE1)
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |